KOREA WHO
-
-
-
CEO of HanAll Biopharma
Jung Seung-won
Aiming to Become Global Biopharma Leader via Clinical Data
-
Last Updated on Mar 23, 2026
-
CEO of HanAll Biopharma
Life Summary
Jung Seung-won is the CEO of HanAll Biopharma.
He was born on December 22, 1971.
He graduated from Yonsei University College of Medicine and completed an MBA program at the MIT Sloan School of Management in the United States.
After working as a consultant at Bain & Company, he moved to Novartis, where he worked as Marketing Manager of the Infectious Diseases Division, Executive Director of the Neuroscience Division at Novartis Korea, and Global Program Director in the Global Strategic Marketing Department.
He also served as Executive Director of Marketing for the Neuroscience Division in Japan and as New Drug Director of the Neuroscience Division at Novartis.
At UCB Pharma, headquartered in Belgium, he oversaw the osteoporosis business for Japan and China.
After serving as Head of HanAll Biopharma’s U.S. subsidiary (HPI) in 2020, he was appointed Co-CEO of HanAll Biopharma in March 2021.
As a former doctor, he is a biotechnology expert who was responsible for clinical development and business strategy for 12 years at global big pharma company Novartis.
He is working to accelerate global clinical development of new biopharmaceuticals such as HL036, a treatment for dry eye disease, and HL161, an antibody treatment for autoimmune diseases, while also seeking to secure new pipelines by strengthening cooperation with multinational pharmaceutical companies.
#HanAllBiopharma #JungSeungwon #biopharma #Novartis #UCBPharma #HL036 #HL161 #clinicaldevelopment #biotechnology #pharmaceuticals
He was born on December 22, 1971.
He graduated from Yonsei University College of Medicine and completed an MBA program at the MIT Sloan School of Management in the United States.
After working as a consultant at Bain & Company, he moved to Novartis, where he worked as Marketing Manager of the Infectious Diseases Division, Executive Director of the Neuroscience Division at Novartis Korea, and Global Program Director in the Global Strategic Marketing Department.
He also served as Executive Director of Marketing for the Neuroscience Division in Japan and as New Drug Director of the Neuroscience Division at Novartis.
At UCB Pharma, headquartered in Belgium, he oversaw the osteoporosis business for Japan and China.
After serving as Head of HanAll Biopharma’s U.S. subsidiary (HPI) in 2020, he was appointed Co-CEO of HanAll Biopharma in March 2021.
As a former doctor, he is a biotechnology expert who was responsible for clinical development and business strategy for 12 years at global big pharma company Novartis.
He is working to accelerate global clinical development of new biopharmaceuticals such as HL036, a treatment for dry eye disease, and HL161, an antibody treatment for autoimmune diseases, while also seeking to secure new pipelines by strengthening cooperation with multinational pharmaceutical companies.
#HanAllBiopharma #JungSeungwon #biopharma #Novartis #UCBPharma #HL036 #HL161 #clinicaldevelopment #biotechnology #pharmaceuticals